Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Longitudinal exposure of English primary care patients to pharmacogenomic drugs: an analysis to inform design of pre-emptive pharmacogenomic testing.

Kimpton JE, Carey IM, Threapleton CJD, Robinson A, Harris T, Cook DG, DeWilde S, Baker EH.

Br J Clin Pharmacol. 2019 Aug 27. doi: 10.1111/bcp.14100. [Epub ahead of print]

PMID:
31454087
2.

Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing.

Lee YM, Danahey K, Knoebel RW, Ratain MJ, Meltzer DO, O'Donnell PH.

Pharmacogenet Genomics. 2019 Feb;29(2):23-30. doi: 10.1097/FPC.0000000000000346.

PMID:
30531378
3.

A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics.

Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, Böhm R, Borg J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši Ľ, Kučinskas V, Khusnutdinova E, Loukas YL, Macek M Jr, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Setric J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, Mc Leod HL, van der Spek PJ, Patrinos GP.

PLoS One. 2016 Sep 16;11(9):e0162866. doi: 10.1371/journal.pone.0162866. eCollection 2016. Erratum in: PLoS One. 2017 Feb 16;12 (2):e0172595.

4.

Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available.

Samwald M, Xu H, Blagec K, Empey PE, Malone DC, Ahmed SM, Ryan P, Hofer S, Boyce RD.

PLoS One. 2016 Oct 20;11(10):e0164972. doi: 10.1371/journal.pone.0164972. eCollection 2016.

5.
6.

Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs.

Kaufman AL, Spitz J, Jacobs M, Sorrentino M, Yuen S, Danahey K, Saner D, Klein TE, Altman RB, Ratain MJ, O'Donnell PH.

Mayo Clin Proc. 2015 Jun;90(6):716-29. doi: 10.1016/j.mayocp.2015.03.016.

7.

Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice.

Cecchin E, Roncato R, Guchelaar HJ, Toffoli G; Ubiquitous Pharmacogenomics Consortium.

Curr Pharm Biotechnol. 2017;18(3):204-209. doi: 10.2174/1389201018666170103103619. Review.

PMID:
28044932
8.

Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation.

Lee YM, McKillip RP, Borden BA, Klammer CE, Ratain MJ, O'Donnell PH.

Pharmacogenet Genomics. 2017 May;27(5):179-189. doi: 10.1097/FPC.0000000000000275.

9.

Clinical practice guidelines for translating pharmacogenomic knowledge to bedside. Focus on anticancer drugs.

Agúndez JA, Esguevillas G, Amo G, García-Martín E.

Front Pharmacol. 2014 Aug 19;5:188. doi: 10.3389/fphar.2014.00188. eCollection 2014.

10.

Characterizing Pharmacogenomic-Guided Medication Use With a Clinical Data Repository.

Mathias PC, Hendrix N, Wang WJ, Keyloun K, Khelifi M, Tarczy-Hornoch P, Devine B.

Clin Pharmacol Ther. 2017 Aug;102(2):340-348. doi: 10.1002/cpt.611. Epub 2017 Jun 5.

11.

Pharmacogenomic potential of psychiatric medications and CYP2D6.

Foley KF, Quigley DI.

MLO Med Lab Obs. 2010 Jan;42(1):32-4.

PMID:
20180465
12.

Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view.

Varnai R, Szabo I, Tarlos G, Szentpeteri LJ, Sik A, Balogh S, Sipeky C.

Pharmacogenomics J. 2019 Dec 2. doi: 10.1038/s41397-019-0123-z. [Epub ahead of print]

PMID:
31787752
13.

Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies.

Rosenblat JD, Lee Y, McIntyre RS.

J Clin Psychiatry. 2017 Jun;78(6):720-729. doi: 10.4088/JCP.15r10583. Review.

PMID:
28068459
14.

Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties.

Johansen Taber KA, Dickinson BD.

Pharmgenomics Pers Med. 2014 Jul 10;7:145-62. doi: 10.2147/PGPM.S63715. eCollection 2014.

15.

Clinical pharmacogenomics: patient perspectives of pharmacogenomic testing and the incidence of actionable test results in a chronic disease cohort.

Mukherjee C, Sweet KM, Luzum JA, Abdel-Rasoul M, Christman MF, Kitzmiller JP.

Per Med. 2017 Sep;14(5):383-388. doi: 10.2217/pme-2017-0022. Epub 2017 Sep 1.

16.

Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.

Drozda K, Müller DJ, Bishop JR.

Pharmacotherapy. 2014 Feb;34(2):166-84. doi: 10.1002/phar.1398. Review.

17.

The Implementation Process for Pharmacogenomic Testing for Cancer-Targeted Therapies.

Wu AC, Mazor KM, Ceccarelli R, Loomer S, Lu CY.

J Pers Med. 2018 Oct 1;8(4). pii: E32. doi: 10.3390/jpm8040032.

18.

Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing.

O'Donnell PH, Wadhwa N, Danahey K, Borden BA, Lee SM, Hall JP, Klammer C, Hussain S, Siegler M, Sorrentino MJ, Davis AM, Sacro YA, Nanda R, Polonsky TS, Koyner JL, Burnet DL, Lipstreuer K, Rubin DT, Mulcahy C, Strek ME, Harper W, Cifu AS, Polite B, Patrick-Miller L, Yeo KT, Leung E, Volchenboum SL, Altman RB, Olopade OI, Stadler WM, Meltzer DO, Ratain MJ.

Clin Pharmacol Ther. 2017 Nov;102(5):859-869. doi: 10.1002/cpt.709. Epub 2017 Jun 15.

19.

Pharmacogenomics in general practice: The time has come.

Polasek TM, Mina K, Suthers G.

Aust J Gen Pract. 2019 Mar;48(3):100-105. doi: 10.31128/AJGP-10-18-4733.

20.

Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling.

Schuck RN, Grillo JA.

AAPS J. 2016 May;18(3):573-7. doi: 10.1208/s12248-016-9891-4. Epub 2016 Feb 24. Review.

Supplemental Content

Support Center